HUM-MOLGEN events: NEURODEGENERATION in Alzheimer's Disease, Parkinson's Disease, & Related Disorders

HUM-MOLGEN -> Events -> Meetings and Conferences

NEURODEGENERATION in Alzheimer's Disease, Parkinson's Disease, & Related Disorders

May 14, 2001

Strategic Research Institute, Hyatt Regency Hotel, Princeton, NJ
July 23-24, 2001

FEATURING:
ALZHEIMER'S B-SECRETASE PROTEIN BACE 1: A TARGET FOR TREATMENT OF ALZHEIMER'S DISEASE-DR. MARTIN CITRON, AMGEN, INC.
THE EVOLUTION OF NEURAL AND STEM CELL THERAPIES FOR PARKINSON'S DISEASE-DR. OLE ISACSON, HARVARD MEDICAL SCHOOL
DEVELOPMENT OF RADIOLIGLANDS FOR IN VIVO IMAGING OF BRAIN AMYLOID-DR. VIRGINIA M.-Y. LEE, UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE
GALANTAMINE: CRESULTS FROM THE CLINICAL DEVELOPMENT PROGRAM-DR. SEAN LILIENFELD, JANSSEN RESEARCHN FOUNDATION
ORGANIZED INTO SIX SECTIONS
-PARKINSON'S DISEASE
-NOVEL THERAPEUTIC TARGETS IN NEURODEGENERATION
-PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE
-AMYLOID PROCESSING
-NOVEL THERAPEUTIC TARGETS IN NEURODEGENERATION
-THERAPEUTIC ADVANCES

Organized by:

sri

Invited Speakers:

AMGEN, INC., JANSSEN RESEARCH FOUNDATION, AVENTIS PHARMACEUTICALS, UNIVERSITY OF PENNSYLVANIA, NEOTHERAPEUTICS, INC., HARVARD MEDICAL SCHOOL, THE R.W. JOHNSON PRI, NEW YORK MEDICAL CENTER, BINZOU PEOPLE'S HOSPITAL, BRIGHAM AND WOMEN'S HOSPITAL, MITOKOR, NEUROCHEM, INC., JOHNS HOPKINS UNIVERSITY, LILLY RESEARCH LABORATORIES, EXELIS, INC., GUILFORD PHARMACEUTICALS, ACADIA PHARMACEUTICALS.

Deadline for Abstracts:

ABSTRACTS HAVE ALREADY BEEN SUBMITTED

Registration:

TO REGISTER CALL 1-888-666-8514

E-mail:

ESINGLETON@SRINSTITUTE.COM

Posted by:

edrilon

Host:

12.3.58.10